Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population

Documenti analoghi

• Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
  di: Cameron, Jodi, et al.
  Pubblicazione: (2014)
• Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
  di: Forgie, Jennifer, et al.
  Pubblicazione: (2014)
• The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
  di: MacRae, Megan, et al.
  Pubblicazione: (2014)
• Use of Omalizumab to treat a nine-year old, with steroid-dependent, allergic asthma, adrenal insufficiency and vertebral compression fractures due to steroid induced severe osteoporosis
  di: Ring, Alicia, et al.
  Pubblicazione: (2011)
• Treatment of moderate to severe pediatric asthma Omalizumab and potential future use of monoclonal antibodies
  di: Wright, Lakiea S., et al.
  Pubblicazione: (2016)